Circular RNA (oRNA) therapeutics platform; merged with Renagade Therapeutics (2024)
Orna Therapeutics is a Watertown, MA circular-RNA (oRNA) company founded in 2019, developing in vivo CAR (isCAR) and other RNA therapeutics. It raised a $221M Series B in August 2022 alongside a Merck partnership worth up to ~$3.5B. In 2024 Orna acquired the $300M-funded startup Renagade Therapeutics (RNA delivery/editing), with Renagade CEO Amit Munshi (former Arena Pharmaceuticals CEO) taking over as Orna CEO — consolidating a circular-RNA leadership position.
Biotech📍 Watertown, MAFounded 2019
Current Valuation
Private
PRIVATE
IPO Outlookprivate
Is Orna Therapeutics going public?
No. Orna Therapeutics is private and has not filed to go public. There is no S-1 on file.
What is Orna Therapeutics' valuation in 2026?
No confirmed valuation is on record for Orna Therapeutics. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Orna Therapeutics filed an S-1?
No public S-1 is on file for Orna Therapeutics.
Who are Orna Therapeutics' investors?
Orna Therapeutics' investors include MPM BioImpact, Merck, ARCH Venture Partners.
Is Orna Therapeutics publicly traded — can you buy Orna Therapeutics stock?
No. Orna Therapeutics is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Orna Therapeutics on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
CEO
Amit Munshi
Founded
2019
HQ
Watertown, MA
Growth
Consolidated circular-RNA leader after absorbing Renagade (2024)
Last Round
Series B — $221M (Aug 2022) · Lead: MPM BioImpact
IPO Status
private
Fundraising Status
Series B · $221M · 4y 1mo ago
private1 disclosed rounds
Funding History
Round
Amount
Date
Lead Investor
Post-Money
Series B
$221M
Aug 2022
MPM BioImpact
—
Vertical Intelligence — Biotech / Gene Therapy
Registered trials
1
1 active · 1 recruiting
Lead phase
Phase 1
most advanced registered study
Focus areas
Healthy Volunteers - Male and Female
Latest trial start
2026-03-16
Name-verified against lead sponsor "Orna Therapeutics, Inc." on ClinicalTrials.gov as of 2026-09-27. Verify on ClinicalTrials.gov ↗
Talent Signal
Hiring trend
▲ Hiring uptrend
+14% vs 2026-08
Open roles
16
via careers page
Product-build share
56%
engineering, research, product, design
Trajectory
expanding
product-led hiring — 56% of open roles build product; the rest are go-to-market and G&A.
No tracked executive churn; open roles trending up.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Clinical trialsResearch & developmentClinical development pipelineCentessa PharmaceuticalsLimmaTech Biologics[Clinical trials](https://lilly.com/science/clinical-trials)
Counted from Orna Therapeutics's live job board as of 2026-09-14; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Founders & Key People
Thomas Barnes
Investors
MPM BioImpact · Merck · ARCH Venture Partners
Products
oRNA circular RNA platform
In vivo CAR (isCAR) therapies
RNA delivery + editing (via Renagade)
Competitors
Sail Biomedicines · Orbital Therapeutics · Therna Biosciences
BiotechRNA TherapeuticsCircular RNATechBio
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.